Enhabit, Inc. (NYSE:EHAB) Given Consensus Rating of “Reduce” by Analysts

Enhabit, Inc. (NYSE:EHAB) has been assigned a consensus recommendation of “Reduce” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $9.35.

Separately, Leerink Partners reiterated a “market perform” rating and set a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a research note on Tuesday.

Enhabit Stock Down 1.3 %

Shares of NYSE:EHAB traded down $0.09 during midday trading on Tuesday, reaching $7.05. The company’s stock had a trading volume of 46,986 shares, compared to its average volume of 579,755. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74. The firm has a market capitalization of $354.47 million, a P/E ratio of -3.03 and a beta of 1.84. The firm has a 50 day moving average of $7.56 and a 200-day moving average of $8.47. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85.

Enhabit (NYSE:EHAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. The business had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. During the same period in the prior year, the business posted $0.03 EPS. On average, research analysts anticipate that Enhabit will post 0.25 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeffrey Bolton purchased 5,000 shares of Enhabit stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the purchase, the director now directly owns 78,877 shares of the company’s stock, valued at $631,804.77. The trade was a 6.77 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enhabit

Several institutional investors and hedge funds have recently added to or reduced their stakes in EHAB. FMR LLC lifted its holdings in shares of Enhabit by 138.4% during the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after buying an additional 1,967 shares during the period. Gladius Capital Management LP bought a new stake in shares of Enhabit in the second quarter worth $31,000. Quarry LP increased its position in Enhabit by 242.2% during the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after acquiring an additional 2,621 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Enhabit in the first quarter valued at about $44,000. Finally, Stoneridge Investment Partners LLC purchased a new position in Enhabit in the third quarter worth about $81,000.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.